Need a specific person's email?
Browse Nykode Therapeutics's employee directory (about 75 employees) and reveal verified emails free.
Nykode Therapeutics's most common email format is FLast@vaccibody.com (ex. JDoe@vaccibody.com), used for 67% of vaccibody.com addresses. Nykode Therapeutics uses 6 email patterns across 2 domains: vaccibody.com and nykode.com. Percentages are the share of addresses within each domain.
| Format | Example | Share of vaccibody.com |
|---|---|---|
| FLast@vaccibody.comMost common | JDoe@vaccibody.com | |
| F.Last@vaccibody.com | J.Doe@vaccibody.com | |
| FL@vaccibody.com | JD@vaccibody.com | |
| FMLast@vaccibody.com | JMDoe@vaccibody.com |
| Format | Example | Share of nykode.com |
|---|---|---|
| FLast@nykode.comMost common | JDoe@nykode.com | |
| FMLast@nykode.com | JMDoe@nykode.com |
Browse Nykode Therapeutics's employee directory (about 75 employees) and reveal verified emails free.
Biotechnology ResearchOslo, Norway51-200 Employees
Nykode Therapeutics is a biotechnology company based in Oslo, Norway, focused on immunotherapy discovery and development. It emphasizes an intelligent, modular platform designed to enable targeted therapeutic approaches. Its work spans cancer-related immunotherapies and autoimmune disease research, as reflected in its clinical investigations and collaborations. As a clinical-stage biopharmaceutical company, it pursues translational programs aimed at delivering innovative immune-based treatments to patients. In January 2026, Barbara Krebs-Pohl was appointed chair of the board, with remuneration for the board approved. Earlier, the company disclosed a collaboration with MSD to evaluate VB10.16 in combination with pembrolizumab for a cervical cancer indication, illustrating its engagement with established partners to advance therapies.
Most common format
FLast@vaccibody.com
Example: JDoe@vaccibody.com
Free with a LeadIQ account. No credit card.
Get a demo and discover why thousands of SDR and Sales teams trust LeadIQ to help them build pipeline confidently.